Archives

FDA grants approval to an oral suspension of edaravone (RADICAVA ORS) for the treatment of amyotrophic lateral sclerosis (ALS).

MDA’s 2022 Clinical & Scientific Conference was the world’s largest meeting on neuromuscular disease care In mid-March, more than 1,000 people gathered in Nashville, Tennessee, for MDA’s 2022 Clinical &…

A growing number of parks and recreation areas accommodate people with disabilities who are looking for adventure with accessibility.

It’s been half a century since University of California, Los Angeles, computer science professor Jacques Vidal coined the term “brain-computer interface” (BCI) and produced the first peer-reviewed papers on the…

MDA’s National Resource Center and Family Support Team work alongside families to help locate financial resources, provide educational materials, and secure prescribed durable medical equipment (DME).

Honorable Robert Pipia’s, a judge in Nassau County, New York living with an undiagnosed neuromuscular disease, shares his story of determination, resilience, and advocacy.

Declared an official “Day of Recognition” by Tennessee Governor Bill Lee, the MDA Tribute Tour celebration in Nashville honored three local champions for the cause.

Researchers seek individuals with or without neuromuscular disease to participate in a research study for a wearable gait sensor belt.

Matthew Lawson, an IT Manager living with SMA shares how he pursued his education, gained employment, and achieved his goal of independence.

FDA grants drug approval to ravulizumab (Ultomiris) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.